Tricida (OTCPK:TCDA.Q) - Aktienkurs, Nachrichten und Analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

TCDA.Q Aktienübersicht

Tricida, Inc. operates as a pharmaceutical company.

TCDA.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

Does not have a meaningful market cap ($580)

+ 3 mehr Risiken

Tricida, Inc. Wettbewerber

Halo Collective

OTCPK:HCAN.F

US$15.1k

Greenrose Holding

OTCPK:GNRS

US$1.8k

Goodbody Health

OTCPK:GDBY.F

US$36.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Tricida
Historische Aktienkurse
Aktueller Aktienkurs	US$0.00001
52-Wochen-Hoch	US$13.85
52-Wochen-Tief	US$0.00001
Beta	0.051
11 Monat Veränderung	-99.89%
3 Monate Veränderung	-99.93%
1 Jahr Veränderung	-100.00%
33 Jahre Veränderung	-100.00%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-100.00%

Aktuelle Nachrichten und Updates

Recent updates

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Dec 14

Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%

Dec 09

Tricida's Veverimer CRL And Regulatory Updates: An Analysis

Nov 17

Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

Oct 29

Aktionärsrenditen

	TCDA.Q	US Pharmaceuticals	US Markt
7D	-99.9%	0.2%	0.4%
1Y	-100.0%	17.1%	22.9%

Rendite im Vergleich zur Industrie: TCDA.Q underperformed the US Pharmaceuticals industry which returned 6.4% over the past year.

Rendite vs. Markt: TCDA.Q underperformed the US Market which returned 14% over the past year.

Preisvolatilität

Is TCDA.Q's price volatile compared to industry and market?
TCDA.Q volatility
TCDA.Q Average Weekly Movement	43.8%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: TCDA.Q's share price has been volatile over the past 3 months.

Volatilität im Zeitverlauf: TCDA.Q's weekly volatility has increased from 31% to 44% over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2013	57	Gerrit Klaerner	www.tricida.com

Tricida, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Tricida im Vergleich zum Marktanteil des Unternehmens?
TCDA.Q grundlegende Statistiken
Marktanteil	US$580.00
Gewinn(TTM)	-US$133.91m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist TCDA.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TCDA.Q Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$133.91m
Umsatz	-US$133.91m

Zuletzt gemeldete Gewinne

Sep 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.31
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	-143.5%

Wie hat sich TCDA.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company is no longer active

TCDA.Q Aktienübersicht

Belohnungen

Risikoanalyse

Tricida, Inc. Wettbewerber

OTCPK:HCAN.F

US$15.1k

OTCPK:GNRS

US$1.8k

OTCPK:GDBY.F

US$36.0

OTCPK:PLXP.Q

US$30.0

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Tricida, Inc. Announces Resignation of David Bonita as Director

Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index

Tricida Receives Delisting Notice from Nasdaq

Motion for Asset Sale Filed by Tricida, Inc.

Tricida, Inc. Filed for Bankruptcy

Tricida Receives Non-Compliance Notice from Nasdaq

Recent updates

Tricida, Inc. Announces Resignation of David Bonita as Director

Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index

Tricida Receives Delisting Notice from Nasdaq

Motion for Asset Sale Filed by Tricida, Inc.

Tricida, Inc. Filed for Bankruptcy

Tricida Receives Non-Compliance Notice from Nasdaq

Tricida Receives A Notice from Nasdaq Regarding Minimum Bid Price

Price target decreased to US$8.00

Insufficient new directors

Tricida, Inc Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Price target decreased to US$15.33

Tricida, Inc. announced that it expects to receive $125 million in funding

Tricida enters $125M debt facility

Tricida: Important Binary Event Coming Up

Tricida, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target increased to US$16.75

Price target decreased to US$15.50

Tricida, Inc Announces Administrative Stop of the VALOR-CKD Trial

Tricida, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$17.50

Insufficient new directors

Tricida, Inc., Annual General Meeting, Jun 15, 2022

Price target increased to US$17.50

Tricida, Inc. Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

Board Member notifies of intention to sell stock

Price target increased to US$20.00

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Board Member notifies of intention to sell stock

Tricida, Inc.(NasdaqGS:TCDA) dropped from Russell 2500 Growth Index

Board Member notifies of intention to sell stock

Tricida, Inc. Provides Update on FDA Interactions

Tricida, Inc. Appoints Geoffrey Parker as Chief Operating Officer

Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the Tricida, Inc. Class Action Lawsuit

New 90-day low: US$6.57

Board Member notifies of intention to sell stock

Block & Leviton LLP Sues Tricida, Inc. for Violations of the Federal Securities Laws

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Tricida, Inc

Law Offices of Howard G. Smith Announces the Filing of Securities Class Action on Behalf of Tricida, Inc. Investors

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Tricida, Inc

Board Member notifies of intention to sell stock

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

CFO & Executive VP recently bought US$102k worth of stock

Tricida, Inc. Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection Through 2038

Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%

Tricida, Inc. Announces Executive Changes

Tricida's Veverimer CRL And Regulatory Updates: An Analysis

Price target lowered to US$13.50

Price target raised to US$22.67

Tricida, Inc. Announces Susannah Cantrell Will Depart from the Position as Executive Vice President and Chief Commercial Officer, Effective from October 30, 2020

Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

New 90-day low: US$8.29

New 90-day low: US$9.33

Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P Pharmaceuticals Select Industry Index

New 90-day low - US$13.24

Price target lowered to US$45.33

New 90-day low - US$15.64

Aktionärsrenditen

Preisvolatilität

Erträge & Einnahmen